Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A
Details : ASC618 is an investigational second-generation gene therapy, which is beingevaluated for the treatment for patients with severe and moderately severe hemophilia A.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : ASC618 is designed to deliver a shortened, but optimized version of the gene to liver cells. ASC Therapeutics has received IND clearance, as well as key regulatory designations in the U.S. and Europe for its ASC618 program.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 13, 2022
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : UMass Chan Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The AAV-based Gene Therapy, was administered via intravenous (IV) injection. Surviving mice grew and behaved similar to normal littermates and had normal or nearly normal biochemical markers with unrestricted diet for 16 weeks.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : UMass Chan Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC618 is a second-generation gene therapy for the treatment of hemophilia A. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : ASC618
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : University of Massachusetts
Deal Size : Undisclosed
Deal Type : Partnership
ASC Therapeutics Partnership With University of Massachusetts Medical School
Details : Under the agreement, the research group at UMMS, and RNA therapeutics, will develop multiple animal models for MSUD, as well as conduct pre-clinical testing using such animal models and proprietary AAV constructs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : University of Massachusetts
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ASC930
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 12, 2021
Lead Product(s) : ASC930
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC61
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASC618 Gene Therapy in Hemophilia A Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : ASC61
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Recipient : Vigene Bioscience
Deal Size : Undisclosed
Deal Type : Partnership
Details : Vigene will provide ASC with access to GMP mfg including viral vectors and plasmid DNA for its Hemophilia A gene therapy clinical program, as well as a manufacturing platform for future programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 14, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Recipient : Vigene Bioscience
Deal Size : Undisclosed
Deal Type : Partnership